Aberrantly Activated APOBEC3B Is Associated With Mutant P53-Driven Refractory/Relapsed Diffuse Large B-Cell Lymphoma

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 May 20

PMID 35592333

Authors

Xuzhao Zhang

Zhaoxing Wu

Yuanyuan Hao

Teng Yu

Xian Li

Yun Liang

Jinfan Li

Liansheng Huang

Yang Xu

Xiuzhen Li

Xiaohua Xu

Weiqin Wang

Genbo Xu

Xiaohong Zhang

Qinghua Lv

Yongming Fang

Rongzhen Xu

Wenbin Qian

Affiliations

Soon will be listed here.

Abstract

Tumor protein 53 () mutation predicts an unfavorable prognosis in diffuse large B-cell lymphoma (DLBCL), but the molecular basis for this association remains unclear. In several malignancies, the cytidine deaminase apolipoprotein B mRNA editing enzyme catalytic subunit 3B (APOBEC3B) has been reported to be associated with the G/C-to-A/T mutation. Here, we show that the frequency of this mutation was significantly higher in relapsed/refractory (R/R) than in non-R/R DLBCL, which was positively associated with the expression level. APOBEC3B overexpression induced the G/C-to-A/T mutation , resulting in a phenotype similar to that of DLBCL specimens. Additionally, APOBEC3B-induced p53 mutants promoted the growth of DLBCL cells and enhanced drug resistance. These results suggest that APOBEC3B is a critical factor in mutant p53-driven R/R DLBCL and is therefore a potential therapeutic target.

Citing Articles

Transcriptome profiling revealed multiple circadian rhythm-related genes associated with common gynecological cancers.

Peng L, Jiang M, Li K, Yu S, Zhao C, Zhang L Front Oncol. 2025; 15:1422122.

PMID: 39944833 PMC: 11813765. DOI: 10.3389/fonc.2025.1422122.

Progress in deciphering the role of p53 in diffuse large B-cell lymphoma: mechanisms and therapeutic targets.

Wen W, Zhang W, Tan R, Zhong T, Zhang M, Fang X Am J Cancer Res. 2024; 14(7):3280-3293.

PMID: 39113862 PMC: 11301306. DOI: 10.62347/LHIO8294.

Human APOBEC3B promotes tumor development in vivo including signature mutations and metastases.

Durfee C, Temiz N, Levin-Klein R, Argyris P, Alsoe L, Carracedo S Cell Rep Med. 2023; 4(10):101211.

PMID: 37797615 PMC: 10591044. DOI: 10.1016/j.xcrm.2023.101211.

APOBEC3B coordinates R-loop to promote replication stress and sensitize cancer cells to ATR/Chk1 inhibitors.

Zong C, Zhang Z, Gao L, He J, Wang Y, Li Q Cell Death Dis. 2023; 14(6):348.

PMID: 37270643 PMC: 10239489. DOI: 10.1038/s41419-023-05867-0.

APOBEC3-mediated mutagenesis in cancer: causes, clinical significance and therapeutic potential.

Butler K, Rouf Banday A J Hematol Oncol. 2023; 16(1):31.

PMID: 36978147 PMC: 10044795. DOI: 10.1186/s13045-023-01425-5.

References

Flynt E, Bisht K, Sridharan V, Ortiz M, Towfic F, Thakurta A . Prognosis, Biology, and Targeting of Dysregulation in Multiple Myeloma. Cells. 2020; 9(2). PMC: 7072230. DOI: 10.3390/cells9020287. View

Roberts S, Lawrence M, Klimczak L, Grimm S, Fargo D, Stojanov P . An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet. 2013; 45(9):970-6. PMC: 3789062. DOI: 10.1038/ng.2702. View

Serebrenik A, Starrett G, Leenen S, Jarvis M, Shaban N, Salamango D . The deaminase APOBEC3B triggers the death of cells lacking uracil DNA glycosylase. Proc Natl Acad Sci U S A. 2019; 116(44):22158-22163. PMC: 6825264. DOI: 10.1073/pnas.1904024116. View

Xu-Monette Z, Wu L, Visco C, Tai Y, Tzankov A, Liu W . Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2012; 120(19):3986-96. PMC: 3496956. DOI: 10.1182/blood-2012-05-433334. View

Frebourg T, Kassel J, Lam K, Gryka M, Barbier N, Andersen T . Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein. Proc Natl Acad Sci U S A. 1992; 89(14):6413-7. PMC: 49511. DOI: 10.1073/pnas.89.14.6413. View

Gu Y, Chen T, Meng Z, Gan Y, Xu X, Lou G . CaMKII γ, a critical regulator of CML stem/progenitor cells, is a target of the natural product berbamine. Blood. 2012; 120(24):4829-39. PMC: 4507036. DOI: 10.1182/blood-2012-06-434894. View

Suspene R, Guetard D, Henry M, Sommer P, Wain-Hobson S, Vartanian J . Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc Natl Acad Sci U S A. 2005; 102(23):8321-6. PMC: 1149401. DOI: 10.1073/pnas.0408223102. View

Yamazaki H, Shirakawa K, Matsumoto T, Hirabayashi S, Murakawa Y, Kobayashi M . Endogenous APOBEC3B Overexpression Constitutively Generates DNA Substitutions and Deletions in Myeloma Cells. Sci Rep. 2019; 9(1):7122. PMC: 6509214. DOI: 10.1038/s41598-019-43575-y. View

Ciriello G, Miller M, Aksoy B, Senbabaoglu Y, Schultz N, Sander C . Emerging landscape of oncogenic signatures across human cancers. Nat Genet. 2013; 45(10):1127-33. PMC: 4320046. DOI: 10.1038/ng.2762. View

10.

Cheson B, Pfistner B, Juweid M, Gascoyne R, Specht L, Horning S . Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25(5):579-86. DOI: 10.1200/JCO.2006.09.2403. View

11.

Hollstein M, Sidransky D, Vogelstein B, Harris C . p53 mutations in human cancers. Science. 1991; 253(5015):49-53. DOI: 10.1126/science.1905840. View

12.

Stambolsky P, Tabach Y, Fontemaggi G, Weisz L, Maor-Aloni R, Siegfried Z . Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell. 2010; 17(3):273-85. PMC: 2882298. DOI: 10.1016/j.ccr.2009.11.025. View

13.

Barzak F, Harjes S, Kvach M, Kurup H, Jameson G, Filichev V . Selective inhibition of APOBEC3 enzymes by single-stranded DNAs containing 2'-deoxyzebularine. Org Biomol Chem. 2019; 17(43):9435-9441. DOI: 10.1039/c9ob01781j. View

14.

Morin R, Assouline S, Alcaide M, Mohajeri A, Johnston R, Chong L . Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas. Clin Cancer Res. 2015; 22(9):2290-300. DOI: 10.1158/1078-0432.CCR-15-2123. View

15.

Harris R, Bishop K, Sheehy A, Craig H, Petersen-Mahrt S, Watt I . DNA deamination mediates innate immunity to retroviral infection. Cell. 2003; 113(6):803-9. DOI: 10.1016/s0092-8674(03)00423-9. View

16.

Xu R, Zhang X, Zhang W, Fang Y, Zheng S, Yu X . Association of human APOBEC3 cytidine deaminases with the generation of hepatitis virus B x antigen mutants and hepatocellular carcinoma. Hepatology. 2007; 46(6):1810-20. DOI: 10.1002/hep.21893. View

17.

Chen T, Meng Z, Gan Y, Wang X, Xu F, Gu Y . The viral oncogene Np9 acts as a critical molecular switch for co-activating β-catenin, ERK, Akt and Notch1 and promoting the growth of human leukemia stem/progenitor cells. Leukemia. 2013; 27(7):1469-78. DOI: 10.1038/leu.2013.8. View

18.

Roschewski M, Staudt L, Wilson W . Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol. 2013; 11(1):12-23. PMC: 7709161. DOI: 10.1038/nrclinonc.2013.197. View

19.

Quesnel S, Verselis S, Portwine C, Garber J, White M, Feunteun J . p53 compound heterozygosity in a severely affected child with Li-Fraumeni syndrome. Oncogene. 1999; 18(27):3970-8. DOI: 10.1038/sj.onc.1202783. View

20.

Li J, Yang L, Gaur S, Zhang K, Wu X, Yuan Y . Mutants TP53 p.R273H and p.R273C but not p.R273G enhance cancer cell malignancy. Hum Mutat. 2014; 35(5):575-84. DOI: 10.1002/humu.22528. View